(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Current Chateaus: Advancement and Style - 2Rediscovering Experience Through Excursions: Individual Travel Stories
- 3Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- 4Radiated Tortoise Faces Rapid Decline in Madagascar
- 5Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- The race to mine the moon is on – and it urgently needs some clear international rules
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide
- Merz says army could be involved in mine-clearing from Hormuz
- Barn Stored Lotus Esprit Turbo Seen After 30 Years
- Real time features for Films and Programs
